Table 3.

Results of treatment and complications, including shunt dysfunction, survival, variceal rebleeding and overt hepatic encephalopathy during the follow-up.

Variables	Viabahn (n ​= ​64)	Fluency (n ​= ​37)	P values
Shunt Dysfunction
0–3 months	1 (1.6%)	5 (13.5%)	0.024
0–6 months	5 (7.8%)	5 (13.5%)	0.491
0–12 months	8 (12.5%)	6 (16.2%)	0.541
Death
0–3 months	2 (3.1%)	3 (8.1%)	0.453
0–6 months	4 (6.3%)	4 (10.8%)	0.460
0–12 months	6 (9.4%)	4 (10.8%)	1.000
Variceal Rebleeding
0–3 months	1 (1.6%)	2 (5.4%)	0.552
0–6 months	3 (4.7%)	2 (5.4%)	1.000
0–12 months	7 (10.9%)	4 (10.8%)	1.000
Overt Hepatic Encephalopathy
0–3 months	11 (17.2%)	8 (21.6%)	0.605
0–6 months	13 (20.3%)	9 (24.3%)	0.863
0–12 months	13 (20.3%)	10 (27.0%)	0.468